# A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

> **NCT03374657** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** CPK850

## Key facts

- **NCT ID:** NCT03374657
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-22
- **Primary completion:** 2026-05-11
- **Final completion:** 2026-05-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374657, "A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03374657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*